Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Want to see JP:4512 full AI Analyst Report?
Top Page
Wakamoto Pharmaceutical Co., Ltd.
(4512)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥261.00
▼(-8.74% Downside)
Action:Reiterated
Date:05/19/26
The score is driven primarily by solid balance-sheet quality and improved recent profitability, but it is held back by persistently negative operating/free cash flow and a weak technical trend (trading below major moving averages). A high P/E and modest dividend yield further limit the valuation support.
Positive Factors
Conservative balance sheet
Very low leverage and a large equity base materially reduce financial risk and grant strategic flexibility. Over a multi-month horizon this conservatism supports funding for R&D, inventory, or acquisitions without immediate refinancing pressure, strengthening resilience to shocks.
Negative Factors
Negative operating and free cash flow
Persistent negative OCF and FCF over multiple years undermines the balance-sheet advantage by draining cash reserves or forcing reliance on non-operational financing. This restricts capacity to self-fund growth, dividends, or one-off investments without eroding liquidity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a large equity base materially reduce financial risk and grant strategic flexibility. Over a multi-month horizon this conservatism supports funding for R&D, inventory, or acquisitions without immediate refinancing pressure, strengthening resilience to shocks.
Read all positive factors
Wakamoto Pharmaceutical Co., Ltd. (4512) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.92B
Dividend Yield1.06%
Average Volume (3M)65.94K
Price to Earnings (P/E)39.3
Beta (1Y)0.44
Revenue Growth27.18%
EPS Growth252.59%
CountryJP
Employees403
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-5.12
Shares Outstanding34,838,326
10 Day Avg. Volume55,010
30 Day Avg. Volume65,936
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.01
Price to Sales (P/S)1.23
P/FCF Ratio-11.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely...
How the Company Makes Money
Wakamoto Pharmaceutical primarily makes money by selling its pharmaceutical and health-related products in Japan. Its revenue model is centered on (1) product sales through distribution channels such as pharmacies, drugstores, and other retail/who...
Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
84
Very Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.98B | 9.91B | 7.79B | 7.74B | 8.66B | 8.38B |
| Gross Profit | 3.75B | 4.73B | 3.62B | 3.54B | 4.11B | 4.36B |
| EBITDA | 397.01M | 701.22M | 438.68M | 504.84M | 575.81M | 755.52M |
| Net Income | -177.67M | 227.22M | 64.44M | 108.96M | 138.26M | 238.54M |
Balance Sheet | ||||||
| Total Assets | 15.25B | 16.50B | 15.00B | 15.42B | 15.71B | 14.95B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 2.01B | 2.95B | 3.66B | 3.88B | 3.23B |
| Total Debt | 100.00M | 400.00M | 100.00M | 130.73M | 529.00K | 2.65M |
| Total Liabilities | 3.55B | 4.49B | 3.39B | 3.39B | 3.80B | 3.47B |
| Stockholders Equity | 11.70B | 12.01B | 11.61B | 12.03B | 11.91B | 11.48B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.05B | -1.04B | -663.02M | 420.76M | -28.97M |
| Operating Cash Flow | 0.00 | -486.91M | -592.45M | -107.34M | 631.92M | 339.17M |
| Investing Cash Flow | 0.00 | -657.56M | -13.50M | -2.35M | 17.13M | 50.57M |
| Financing Cash Flow | 0.00 | 195.88M | -103.94M | -104.99M | -1.61M | -1.62M |
Wakamoto Pharmaceutical Co., Ltd. Technical Analysis
Negative
286.00
Price Trends
308.12
Negative
318.53
Negative
303.76
Negative
Market Momentum
-16.01
Negative
34.99
Neutral
61.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 286 is above the 20-day moving average (MA) of 262.80, below the 50-day MA of 308.12, and below the 200-day MA of 303.76, indicating a bearish trend. The MACD of -16.01 indicates Negative momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 61.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.
Wakamoto Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥13.22B | 25.13 | ― | ― | 1.62% | -25.43% | |
63 Neutral | ¥8.77B | 14.02 | ― | 2.55% | -0.61% | 14.60% | |
63 Neutral | ¥34.24B | 12.06 | ― | 2.75% | 3.94% | 40.63% | |
53 Neutral | ¥8.92B | 39.26 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥18.26B | 8.74 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥15.56B | 36.14 | ― | 3.65% | 8.42% | 49.52% |
* Healthcare Sector Average
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
257.00
-46.44
-15.31%
JP:2929
Pharma Foods International Co., Ltd.
537.00
-303.51
-36.11%
JP:4524
Morishita Jintan Co., Ltd.
2,151.00
91.09
4.42%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,082.00
76.76
3.83%
JP:4574
Taiko Pharmaceutical Co., Ltd.
264.00
-95.00
-26.46%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,187.00
223.35
23.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.